Report Publication Announcement • Jun 20, 2022
Report Publication Announcement
Open in ViewerOpens in native device viewer
News Details
Ad-hoc | 20 June 2022 23:20
Achiko AG – Publication of Annual Report and Annual Financial Statements 2021 to Occur by 26 June 2022
Achiko AG / Key word(s): Miscellaneous
20-Jun-2022 / 23:20 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Achiko AG – Publication of Annual Report a nd Annual F inan c ia l S t a t emen t s 2021 t o Occur by 26 June 2022
Zurich, 20 J u ne 2022: Ad hoc an n o u ncement pu r su a nt to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual report and its annual financial statements for the year 2021 on 26 June 2022 at the latest. As a company listed on SIX, Achiko is required to publish its annual report, together with the annual financial statements, within four months of the balance sheet date. Due to the Covid-19 pandemic, new staffing and training under difficult conditions in consequence of measures taken by several countries required a lot of management capacity. As a result, the publication of the annual report 2021, together with the annual financial statements and the audit report, will occur in the month of June 2022. Achiko has filed an exemption request with SIX Exchange Regulation (SER) regarding the publication of the annual report and the annual financial statements 2021. On 28 April 2022, SER granted Achiko the requested extension. Achiko filed a second extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 30 May 2022, SER granted Achiko the second extension. Achiko filed a third extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 3 June 2022, SER granted Achiko the third extension. On 10 June 2022, Achiko filed a fourth extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 10 June, SER granted Achiko the fourth extension. On 20 June 2022, Achiko filed a fifth extension request with SER regarding the publication of the annual report and the annual financial statements 2021. On 20 June, SER granted Achiko the fifth extension. The delay is a function of the matters announced previously including continuity of operations in the second half of the financial year as a result of the Covid-19 pandemic and the higher than expected manual administrative workload, in particular regarding the auditory reconciliation documentation. In addition, the Company’s CEO contracted Covid-19 during the calendar week 23/2022 limiting his ability to compile the relevant accounting documentation swiftly and interact with others in physical meetings.
As required by SER, Achiko hereby reprints para. I of SER’s respective decision:
“The exemption application of Achiko (Issuer) dated 20 June 2022 requesting a fifth extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG until 26 June 2022 at the latest is granted with the following reservation (lit. a) and under the following conditions (lit. b):
˗ the unaltered reproduction of the wording of para. I. of this decision, placed in a prominent position;
˗ the reasons for the application of the Issuer requesting a fifth extension of the deadline to publish its 2021 annual report and to file such report with SIX Exchange Regulation AG.”
The date of the next annual general meeting will be announced in due course, once the Company has published its annual report and its annual financial statements for the year 2021.
ABOUT ACHIKO A G
Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com ) is developing disruptive diagnostic
solutions that puts people first. The company’s lead product is a rapid, reliable Covid-19 test with a
companion app offering a user-friendly digital health passport. The test and companion app were
launched in Indonesia in mid-2021 and an application for CE Mark approval in Europe will be submitted in 2022.
Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX TM and companion health apps via its digital mobile health technology division, Teman Sehat TM . The
AptameX DNA aptamer tests can be rapidly chemically synthesised, are cost-effective and have wide
potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to
deliver fast, accurate and affordable diagnostic testing for a range of pathogenic diseases and
therapeutic indications in the rapidly evolving healthcare diagnostics field.
Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.
M edia contacts:
ACHIKO AG
Switzerl and & G lo b al
Marcus Balogh
Farner Consulting Ltd.
T: +41 44 266 67 67
Disclaimer
This communi c a tio n expressl y or i m plicitly c o nta i ns certa i n f or w ard-look i ng s tatem e nts c o ncernin g A chik o A G an d it s business . Suc h stat e ment s in v olv e certai n k n o w n a n d un k no w n risks, uncer t ainties a n d othe r f actors, w hi c h coul d cause the actua l results, f i n ancial c o nditi o n, per f or m ance or achi e vement s o f A chik o A G to be material l y di ff erent f rom any f u t ure results, pe r f ormance or achiev e ments expressed or implie d by such f or w ard-l o oki n g statem e nts. A chiko A G is providing this com m uni c ati o n as o f this date and d oe s not u nder t ake to u p d ate a n y f or w ard- l ooki n g stat e ments contain e d herein as a result o f ne w in f ormat i on , future eve n ts or o ther w ise.
End of ad hoc announcement
| Language: | English |
| Company: | Achiko AG |
| Tessinerplatz 7 | |
| 8002 Zurich | |
| Switzerland | |
| E-mail: | [email protected] |
| Internet: | https://www.achiko.com/ |
| ISIN: | CH0522213468 |
| Valor: | 48788430 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1379755 |
| End of Announcement | EQS News Service |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.